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Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year
survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early
humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their
diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.
Methods and results: The serum reactivity of GEM from inception to invasive cancer, and in resectable or
advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine
and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six
antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the
highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The
diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC
analyses (P < 0.0001). This observation was confirmed in prediagnostic sera from the EPIC prospective study in
patients who eventually developed PDAC (with a mean time lag of 61.2 months between blood drawing and
PDAC diagnosis). A combination of Ezrin-autoantibodies with CA19.9 serum levels and phosphorylated α-Enolase
autoantibodies showed an overall diagnostic accuracy of 0.96 ± 0.02.
Conclusions: Autoantibodies against Ezrin are induced early in PDAC and their combination with other serological
markers may provide a predictive and diagnostic signature.
Keywords: Pancreatic ductal adenocarcinoma, Tumor antigen, Genetically engineered mouse model, Early
diagnosis, EzrinBackground
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer death in Western countries. Upon
diagnosis, less than 20% of patients present localized,
potentially curable tumors. The overall 5-year survival rate
is <5% [1,2]. This poor prognosis has been attributed to
failure in early disease diagnosis, when the tumor may still* Correspondence: franco.novelli@unito.it
1Center for Experimental Research and Medical Studies (CeRMS), Azienda
Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
2Department of Molecular Biotechnology and Life Sciences, University of
Torino, Turin, Italy
Full list of author information is available at the end of the article
© 2013 Capello et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbe resectable, along with its propensity to disseminate and
its resistance to systemic treatment [3]. CA19.9 is the only
biomarker that has demonstrated clinical value for thera-
peutic monitoring and early detection of recurrent disease
after treatment in patients with known pancreatic cancer.
However, its use as a screening tool has proved unsuccess-
ful, thus other biomarkers alone or in combination with it
are required for early diagnosis of PDAC [1].
Autoantibody levels can function as diagnostic and
prognostic markers [4,5]. By SERological Proteome Ana-
lysis (SERPA) we have previously identified a number of
PDAC-associated antigens that are specifically recognizedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PDAC patients [6-9]. However as these autoantibodies
were discovered in sera from patients at advanced stages
of PDAC, earlier diagnostic markers would not have been
identified.
Genetically engineered mice (GEM) that spontan-
eously develop PDAC may be used to facilitate the
development of novel tests for the early detection and
treatment of PDAC [10]. LSL-KrasG12D/+; Pdx-1-Cre
mice (KC) develop the entire histologic compendium of
pancreatic intraepithelial neoplasia (PanIN) lesions ob-
served in the human disease, and a subset of mice also de-
velop invasive pancreatic carcinomas. LSL-KrasG12D/+;
LSL-Trp53R172H/+; Pdx-1-Cre double mutant mice (KPC),
develop a more aggressive invasive and metastatic PDAC
with an earlier time of onset, and display a reduced sur-
vival rate compared to KC mice [11,12].
In the present study, we used SERPA to identify TAAs
eliciting an early humoral response in KC and KPC.
Results from two-dimensional electrophoresis (2DE),
Western blotting (WB) and mass spectrometry (MS)
were combined to compare the reactivity of KC and
KPC sera to that of corresponding matched controls.
Antigens recognized by autoantibodies in KC and KPC
at PanIN stages were identified and validated in a set of
resectable and advanced PDAC patients. Ezrin (EZR),
the protein with the highest frequency of autoantibodies
in both early stage GEM and resectable PDAC patients,
was validated by ELISA test using PDAC sera either
collected at the time of diagnosis or several months
before cancer onset (prediagnostic PDAC). The sensitivity
and specificity of EZR-autoantibodies for discriminating
PDAC was evaluated together with other serological
markers.
Methods
Murine study
All animals were treated in accordance with European and
institutional guidelines (Legislative Order No. 116/92).
129SvJae/B6 H-2Db mice carrying mutated KrasG12D and
Trp53R172H under the endogenous promoter, and flanked
by Lox-STOP-Lox cassettes (LSL-KrasG12D/+ and LSL-
Trp53R172H/+) were kindly provided from Dr. D.A. Tuveson
(Cancer Research UK, Cambridge Research Institute,
Cambridge, UK). C57BL/6 mice expressing Cre recom-
binase under a specific pancreatic transcriptional factor
Pdx-1 (pancreatic duodenum homeobox 1) promoter
(Pdx-1-Cre) were obtained from Dr. A.M. Lowy (University
of California, San Diego, CA). Conditional LSL-KrasG12D/+,
LSL-Trp53R172H/+ and Pdx-1-Cre strains were bred to
obtain LSL-KrasG12D/+; Pdx-1-Cre single mutant (KC) and
LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre double
mutant (KPC) mice [11,12]. To collect serum, mice were
euthanized and blood was collected by cardiac punctureusing a 22-gauge needle and 1 ml syringe. Mice were
surgically and pathologically examined to confirm the
presence of pancreatic tumors and metastases.
Human studies
Cross-sectional clinical study
The study was approved by the Ethical Committees of:
Azienda Ospedaliera Città della Salute e della Scienza di
Torino, Turin; Policlinico G.B. Rossi, Verona; Regina
Elena National Cancer Institute, Rome and Ordine
Mauriziano Hospital, Turin. Serum samples were iso-
lated from venous blood at time of diagnosis with the
informed consent of patients and control subjects and
stored at −80°C until use. De-identified numeric specimen
codes were used to protect the identity of the individuals.
Diagnosis of PDAC or any other cancer was consistently
confirmed by histological or cytological analysis. Sera from
120 PDAC patients (M/F: 67/53; median age, 67 y; range,
32–86 y) with clinical features previously described [9]
were analyzed by SERPA, and sera from 69 PDAC patients
with clinical features described in Table 1 were tested by
ELISA. Reactivity of these sera was compared, in both
SERPA and ELISA studies, with that of control sera from
the following sources: 60 healthy subjects (HS, M/F: 25/35;
median age, 70 y; range, 49 − 90 y) with no prior history of
cancer or autoimmune disease; 50 non-PDAC cancer
patients (9 liver, 12 breast, 9 colon, 19 lung and 1 ovarian;
M/F: 24/26; median age, 69 y; range, 44 − 86 y); 46 chronic
pancreatitis patients (CP, M/F: 26/20; median age, 58 y;
range, 22 − 74 y); 12 autoimmune diseases patients (AD, 3
Mixed Cryoglobulinemia, 2 Meniere's Syndrome, 4 Rheu-
matoid Arthritis, 2 Systemic Lupus Erythematosus, and 1
Autoimmune Pancreatitis; M/F: 3/9; median age, 49 y;
range, 38 − 79 y).
Prospective pre-clinical study
Prediagnostic serum samples of PDAC patients and
matched controls were obtained from the Turin European
Prospective Investigation into Cancer and Nutrition
(EPIC) cohort that includes samples from 10 604 healthy
subjects at the moment of enrolment (6 047 males and 4
557 females, aged 35–65 y) recruited in the city of Turin.
Recruitment took place between 1993–1998 and involved
blood donors and other healthy volunteers. After blood
donation, samples were stored at 5–10°C, protected from
light, and transported to local laboratories for processing
and dividing into aliquots. Blood was separated into
0.5-ml fractions (serum, plasma, red cells, and buffy coat
for DNA extraction) and stored in heat-sealed straws in
liquid nitrogen (−196°C). Subjects were monitored longi-
tudinally for cancer or other disease development. Co-
operation with the local cancer registry and the local
health authority enabled access to hospital discharge in-
formation and all newly diagnosed cancer cases. Study
Table 1 Clinical features of PDAC patients analyzed by
ELISA
Characteristics N %a
Gender
Male 39 57
Female 30 43
Age (y)
Mean 63 - -
Range 42-84 - -
Stageb
IB 1 2
IIA 7 10
IIB 29 42
III 10 14
IV 22 32
Grading
Not reported 32 46
1 4 6
2 16 23
3 17 25
Primary site
Head 49 71
Body 6 9
Tail 5 7
Body-Tail 9 13
ECOG PS
Not reported 10 14
0 32 47
1 25 36
≥2 2 3
Surgery with radical intent
Yes 39 57
No 30 43
Baseline CA19.9 (IU/ml)
Evaluable 63 91
Mean 3052 - -
Median 500 - -
Range 2- > 12000 - -
First-line chemotherapyc
Evaluable 59 86
Gem 43 73
Gem/Oxal 10 17
Gem/5-FU 3 5
Non-Gem 1 2
No CT 2 3
Table 1 Clinical features of PDAC patients analyzed by
ELISA (Continued)
ENOA1,2 Reactivity
Evaluable 50 73
Positive 34 68
Negative 16 32
ECOG PS eastern cooperative oncology group performance status,
5-FU 5-fluorouracil, Gem gemcitabine, Oxal oxaliplatin, CT chemotherapy.
aRounded percentages.
bClassified according to the TMN classification of malignant tumor of the
pancreas (UICC).
cFirst-line chemotherapy refers to palliative chemotherapy administered for
relapsed, locally advanced inoperable, or metastatic disease.
Capello et al. Journal of Hematology & Oncology 2013, 6:67 Page 3 of 12
http://www.jhoonline.org/content/6/1/67design, population and baseline data collection have pre-
viously been described in detail [13,14]. Sixteen PDAC
patients identified from the Turin EPIC cohort are inclu-
ded in the present study. Controls were matched by age,
sex, and date at entry in the cohort, and did not develop
any cancer or autoimmune disease. Characteristics of sub-
jects are summarized in Table 2. Each participant provided
informed consent, and the local Ethics Review Committees
approved this study.
Two-dimensional electrophoresis and western blot analysis
Cells (107) from the CF-PAC-1 (ECACC ref. No. 91112501)
and K8484 isolated from a tumor arising in KPC mice,
kindly provided by Dr. K.P. Olive (Columbia University,
New York, NY), were solubilized, subjected to 2DE and
electro-transferred onto a nitrocellulose membrane (GE
Healthcare Bio-Sciences, Uppsala, Sweden) as previ-
ously described [6]. Frozen PDAC tissues from eight
surgically-treated patients (stage IIA and IIB of PDAC)
were homogenized in 2DE lysis buffer, subjected to
2DE and electro-blotted onto a nitrocellulose mem-
brane (GE Healthcare) as previously described [9]. Sera
from KC, KPC, PDAC patients and controls were tested
to determine mouse and human IgG concentrations
using commercial kits (IgG ELISA Quantitation SetTable 2 Characteristics of the EPIC cohort subjects
PDAC Controls
N % N %
Total 16 100 32 100
Age (y)
Mean 54.9 55.1
SD 7.3 7.5
Sex
Female 7 44 14 44
Male 9 56 18 56
Time span to diagnosis (mo)
Mean 61.2
Range 5–117.1
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Sera were individually tested on 2DE maps at a working
dilution of 0.1 mg/ml IgG for 4 h, followed by incuba-
tion with horseradish peroxidase (HRP)-conjugated
rabbit anti-human IgG (90 minutes, 1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or sheep anti-
mouse Ig (90 minutes, 1:5000; GE Healthcare) as a
secondary antibody. Ezrin spots were revealed with anti-
Ezrin antibody (1 hour incubation, 1:5000; Abcam,
Cambridge, MA, USA) and HRP-conjugated donkey
anti-rabbit IgG (1 hour incubation, 1:2000; GE Healthcare)
as a secondary antibody. Immunodetection was accom-
plished by ECL PLUS (Enhanced Chemiluminescence, GE
Healthcare). The chemifluorescent signals were scanned
with “ProXPRESS 2D” (PerkinElmer, Waltham, MA, USA)
with an excitation/emission filter setting of 460/80 and
530/30, respectively, for an exposure time of 12 s. Images
were recorded in TIFF format. The volume of each spot
recognized by autoantibodies was calculated after back-
ground subtraction using “ProFinder 2D” (PerkinElmer)
software and reported as arbitrary units (AU). For proteins
represented from more than one spot the volume was
expressed as a mean value.
Protein identification by mass spectrometry
Coomassie G-stained spots were excised from 2DE pre-
parative gels; destaining and in-gel enzymatic digestion
were performed as previously described [15]. Briefly each
spot was destained with 100 μl of 50% vol/vol aceto-
nitrile in 5 mmol/l ammonium bicarbonate and dried
with 100 μl of acetonitrile. Each dried gel piece was
rehydrated for 40 minutes at 4°C in 10 μl of a digestion
buffer containing 5 mmol/l ammonium bicarbonate, and
10 ng/μl of trypsin. Digestion was allowed to proceed
overnight at 37°C and peptide mixtures were stored at 4°C
until assayed. All digests were analyzed by a MALDI micro
MX - TOF Mass Spectrometer (Waters, MA, USA)
equipped with a delayed extraction unit. Peptide solution
was prepared with equal volumes of saturated α-cyano-4-
hydroxycinnamic acid solution in 40% vol/vol acetonitrile-0
.1% vol/vol trifluoroacetic acid. The MALDI-TOF was cali-
brated with a mix of PEG (PEG 1000, 2000 and 3000 with
the ratio 1:1:2) and mass spectra were acquired in the
positive-ion mode. Peak lists were generated with
ProteinLynx Data Preparation (ProteinLynx Global Server
2.2.5) using the following parameters: external calibration
with lock mass using mass 2465.1989 Da of ACTH, back-
ground subtract type adaptive combining all scans,
performing deisotoping with a threshold of 1%. The 25 most
intense masses were used for database searches against the
SWISSPROT database (Release 2011_12 of 14-Dec-11)
using the free search program MASCOT 2.3.02 (http://
www.matrixscience.com/cgi/search_form.pl?FORMVER=2&
SEARCH=PMF). The following parameters were used in thesearches: taxa Homo sapiens or Mus musculus, trypsin di-
gest, one missed cleavage by trypsin, carbamidomethylation
of cysteine as fixed modification, methionine oxidation as
variable modifications and maximum error allowed 100
ppm. Only proteins with a Mascot score >55 were taken into
consideration.
Anti-Ezrin autoantibody capture by enzyme-linked
immunosorbent assay
Purified recombinant protein of Homo sapiens Ezrin, tran-
script variant 1 (OriGene, Rockville, MD, USA) was used
to capture autoantibodies to Ezrin. Briefly, the protein was
coated (0.5 μg/ml in PBS) on 96-well micro-plates over-
night at room temperature, followed by blocking with PBS
containing 4% bovine serum albumin for 2 hours at room
temperature. Sera (working dilution 0.01 mg/ml) were
then added to the coated wells for 2 hours at room
temperature. After washing with PBS-Tween-20, micro-
plates were incubated with HRP-conjugated rabbit anti-
human IgG (dilution 1:1000; Santa Cruz Biotechnology)
for 1 hour at room temperature and TMB One Solution
(Promega, Madison, WI, USA) was added to each well.
The reaction was stopped by 2N HCl and the optical
density (OD) value was measured at 450 nm. The corre-
sponding background values of the sera on uncoated wells
were subtracted. All samples were assayed in triplicate
and the results represent mean values.
Statistical analysis
Statistical analysis was performed using GraphPad
(Version 4, San Diego, CA), MedCalc (Version 11.4.2.0,
Mariakerke, Belgium) and SPSS (Version 18.0, Chicago,
IL, USA) software packages. Mouse survival was estimated
by Kaplan-Meier analysis and compared with Log-rank
tests. Receiver operating characteristic (ROC) curve ana-
lysis was performed in order to find the optimal cut-off
levels capable of splitting patients into groups with differ-
ent outcome probabilities. Specificity, sensitivity and area
under curve (AUC) were estimated considering histology
results as the gold standard. The classification and regres-
sion tree (CART) analysis, a type of decision tree method-
ology, is a nonparametric statistical procedure that
identifies mutually exclusive and exhaustive subgroups of
a population whose members share common characteris-
tics that influence the dependent variable of interest.
CART uses a binary recursive partitioning method that
produces a decision tree that identifies subgroups of pa-
tients with a higher likelihood of being found positive in a
test for a disease state. The exhaustive CHAID method
was used for CART analysis. Correlations and associations
between variables were tested by Pearson’s test, Student's
t-test, χ2 test or Fisher’s exact test, as appropriate. For all
tests, 2-sided P < 0.05 (*), P < 0.005 (**) and P < 0.0005
(***) values were considered significant.
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Murine study
Serological proteome analysis in mice that spontaneously
develop PDAC
To identify tumor antigens associated with early PDAC
development, we exploited two sophisticated mouse
models of PDAC, KC and KPC mice, in which we could
collect serum from inception of preinvasive disease to
invasive cancer. KC and KPC displayed stereotypical
neoplastic progression from pancreatic precursor lesions
(PanIN) present at 1 month of age to advanced PDAC,
showing a mean survival of 12 and 7 months, respectively
(Additional file 1: Figure S1A). Percentages of transformed
foci increased with age, ranging from less than 5% at 1
month of age to more than 80% at 9 and 5 months
respectively (Additional file 1: Figure S1B-G). Serum
samples collected from 25 KC at 1, 3, 5 and 9 months ofFigure 1 SERPA analysis of KC and KPC serum reactivity against K848
separated by 2DE as described in the Methods section. Samples were focu
range, separated in the second dimension in 4-12% acrylamide gels and su
nitrocellulose membrane and probed with mouse sera. Three representativ
(C) or KPC (D) serum. Immunoreactive protein spots were determined for e
spot pattern of the corresponding Blue Coomassie stained gel using the “P
proteins specifically recognized by KC and KPC sera and identified by MALD
file 1: Table S1.age, and from 16 KPC at 2, 5 and 7 months of age were
histologically attributed to different stages of tumor pro-
gression and subjected to SERPA. Total proteins extracted
from the KPC-derived K8484 cell line were separated by
2DE and transferred onto nitrocellulose membranes. Sera
from GEM or age-matched Pdx-1-Cre mice (hereafter
defined as control mice) were screened individually for
the presence of antibodies to PDAC proteins. Image ana-
lysis of the immunoreactivity identified 18 protein spots
recognized at high frequency by KC and KPC sera com-
pared to control mice sera (Figure 1A-D). These spots
were excised from a preparative gel for MALDI-TOF ana-
lysis, leading to identification of nine proteins (Additional
file 1: Table S1) belonging to three different functional
groups, mainly cytoskeletal proteins or cytoskeleton regula-
tors: Ezrin (EZR), Vimentin (VIM), Cytokeratin-8 (K2C8),
Vinculin (VCL), Annexin A2 (ANXA2) and Annexin A14 cell line 2DE map. Total lysates from the K8484 cell line were
sed in the first dimension using a gradient spanning the indicated pH
bsequently Blue Coomassie stained (A) or transferred to a
e Western blot images show the immunoreactivity of control (B), KC
ach serum by superimposition of immunoblot signal pattern with the
roFinder 2D” software. Numbered circles indicate immunoreactive
I-TOF MS. Immunoreactive protein names are listed in Additional
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protein 2 (FUBP2) and Heterogeneous nuclear ribonu-
cleoprotein L (hnRNPL) and a multifunctional protein:
Programmed Cell Death-6 Interacting protein (PDC6I).
The frequency of IgG to these proteins ranged between 0
and 44% for control mice, and between 25 and 100% for
GEM sera (Figure 2A-B). Even the intensity of the reactivityFigure 2 Individual KC and KPC serum reactivity against the identifie
KPC (B) serum against each MALDI-TOF MS identified protein is represente
volume (Vol) of each immunoreactive spot was calculated after backgroun
reported as arbitrary units (AU). For proteins represented from more than oof IgG to the identified proteins was significantly higher in
GEM compared to matched controls (Figure 2A-B); 2DE
WB performed with serum serial dilution displayed a
higher titer of autoantibodies to these specific proteins in
GEM compared to controls (data not shown). All anti-
gens, and particularly EZR, VCL, VIM, PDC6I, hnRNPL
and ANXA2 induced a specific antibody response in KCd antigens. The intensity of reactivity of each control Cre, KC (A) and
d as a gray gradient scale of color as described in the legend. The
d subtraction with the image analysis software “ProFinder 2D” and
ne spot the volume was expressed as mean AU value.
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when the tumor stage was limited to early PanIN
(Additional file 1: Figure S1B and E).Human studies
Serological proteome analysis in human PDAC
To validate in PDAC patients the autoantibody signature
identified in GEM, sera from 120 PDAC patients, 40
healthy subjects (HS), 50 non-PDAC tumor patients (non-
PDAC), 46 chronic pancreatitis (CP) and 12 autoimmune
disease (AD) patients, previously screened against α-
enolase (ENOA) isoforms [9], were compared for reactiv-
ity against whole protein extracts of the CF-PAC-1 human
PDAC cell line, resolved by 2DE. Only six antigens (EZR,
ANXA2, VCL, hnRNPL, ANXA1 and PDC6I), represented
by 12 spots, induced specific IgG in PDAC patients like in
GEM with a frequency from 19% to 56% (Additional file
1: Figure S2 and Table S2 and Table 3).
IgG to these common antigens were not only present
in advanced PDAC patients (n = 82), but also in the
group of stage II and III resectable patients who under-
went surgery with curative intent (n = 38). In this set of
patients, there was a statistically significant frequency
of autoantibodies against common antigens, with the
exception of PDC6I, compared to controls; in parti-
cular, EZR and ANXA2 were recognized by 68 and 63%
of resectable PDAC patients, respectively (Figure 3A).
Moreover, for eight surgically-treated patients with
stage IIA/IIB PDAC the antigen immunoreactivity was
not only confirmed on the CF-PAC-1 cell lysate, but
also on the autologous tumoral biopsy 2DE map
(Figure 3B).Table 3 Frequencies of sera reactivity against protein spots in
Spot no.a Protein PDAC non-PD
(N = 120) (N = 50)
1-4 VCL 31% 0%
P < 0.000
5 PDC6I 21% 0 (0%)
P < 0.000
6-9 EZR 56% 12%
P < 0.000
10 hnRNPL 35% 4%
P < 0.000
11 ANXA1 19% 0%
P = 0.000
12 ANXA2 53% 8%
P < 0.000
aReactive protein spots numbered as shown in Additional file 1: Figure S2. Frequen
between PDAC and each control group, P-values < 0.05 were considered statisticallyCross-sectional clinical study: detection of anti-Ezrin
autoantibodies
EZR was the antigen recognized at the highest frequen-
cies by sera from both GEM at early stages of the disease
and resectable PDAC patients, and its identification was
later proved through 2DE WB in K8484, CF-PAC-1 cells
and PDAC tissues (Additional file 1: Figure 1). This ana-
lysis confirmed the presence of different EZR isoforms
both in murine and human PDAC, likely due to different
post-translational modifications (e.g. phosphorylation).
Moreover, to approach the issue through a method-
ology with a wider clinical employment, we set up an
ELISA test to validate 2DE WB results. The ability of
sera from advanced (n = 30) and resectable (n = 39)
PDAC patients (Table 1) to react against human re-
combinant EZR was compared to that of sera from HS
(n = 45), non-PDAC tumor (n = 28; 8 breast, 8 colon, 12
lung cancer), CP (n = 37) and AD patients (n = 12).
PDAC sera displayed specific reactivity to EZR protein
(P < 0.0001, Figure 4A), but not to ANXA2, another pro-
tein recognized with a high frequency by resectable
PDAC patients in 2DE WB (data not shown). The ELISA
approach also confirmed the presence of autoantibodies
against EZR in both KC and KPC, where there was a sig-
nificant increase of autoantibody levels against recom-
binant EZR compared to control mice (data not shown).
Prospective pre-clinical study: validation of anti-Ezrin
autoantibodies
To investigate the occurrence of autoantibodies to EZR
several months before PDAC diagnosis, we took advan-
tage of the serum specimens from the European Prospect-
ive Investigation into Cancer and Nutrition (EPIC) cohortanalyzed groups
AC CP AD HS
(N = 46) (N = 12) (N = 40)
9% 0% 5%
1 P = 0.0024 P = 0.0193 P = 0.0005
7% 0% 3%
1 P = 0.0361 P = 0.1221 P = 0.0033
2% 17% 10%
1 P < 0.0001 P = 0.0135 P < 0.0001
12% 0% 5%
1 P = 0.0006 P = 0.0039 P < 0.0001
2% 0% 0%
3 P = 0.0053 P = 0.2198 P = 0.0012
28% 0% 10%
1 P = 0.0052 P = 0.0003 P < 0.0001
cies are expressed as percentage of positive sera; Fisher’s test was performed
significant.
Figure 3 Antigen validation in resectable PDAC patients. (A) The graph shows the frequency of autoantibodies against mouse and human
common immunoreactive antigens in the group of resectable patients who underwent surgery with curative intent (n = 38), analyzed by SERPA
against CF-PAC-1 cell line 2DE map. P-values were calculated vs. control frequencies listed in Table 3 by Fisher's exact test (** P < 0.005). (B)
Proteins were extracted from eight frozen PDAC tissues from surgically-treated patients (stage IIA and IIB), separated by 2DE, transferred to a
nitrocellulose membrane and probed with the autologous serum. A representative Western blot is shown; circles indicate the presence of
autoantibodies against the mouse and human common immunoreactive antigens.
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teers monitored longitudinally for cancer or other diseases
development over the years. Sixteen prediagnostic PDAC
patient specimens, with a time span to diagnosis of 5–
117.1 mo (mean, 61.2 mo), and thirty-two matched con-
trols from the Turin EPIC cohort were used for this study.
Controls were matched for age, sex, and date of enrollment
(Table 2). Notably, the level of autoantibodies to EZR was
significantly higher in prediagnostic PDAC serum samples
compared to matched controls (P = 0.0002), showing a
similar trend of reactivity in both newly diagnosed and
prediagnostic PDAC sera (Figure 4B). Detailed time lag to
diagnosis and ELISA values for each PDAC patient of the
EPIC cohort are shown in Additional file 1: Table S3.
Analysis of diagnostic performance and clinical
correlations
These ELISA results prompted us to use ROC analysis to
assess the diagnostic performance of EZR-autoantibody
detection. The analysis performed, using OD obtained in
ELISA as a continuous variable, showed the greatest
discriminating power between PDAC patients (n = 69) and
benign controls (HS, CP and AD patients, n = 94) at a
cut-off level of 0.1183 (sensitivity 93.2%, specificity 75.5%,
AUC 0.90 ± 0.03; Figure 4C). With reference to the same
cut-off, the ELISA test was also very efficient in dis-
criminating between PDAC patients and patients with
non-PDAC malignancies, with 94.9% sensitivity, 96.4%
specificity, and an AUC of 0.99 ± 0.01 (data not shown).
Thus we dichotomized the EZR-autoantibody variables into
positive and negative according to the above-mentioned
cut-off level (0.1183) for all subsequent analyses.
Dichotomized EZR-autoantibody levels did not show
any correlation with clinical parameters (age, gender,stage at diagnosis, ECOG PS). However, mean and
median OD values were significantly (P = 0.030) higher
in PDAC patients who had undergone radical surgery
(see also ROC analysis in Additional file 1: Figure S4,
right panel).
We have previously demonstrated that autoantibodies
to ENOA1,2, two phosphorylated isoforms of ENOA, use-
fully complement the diagnostic performance of CA19.9
serum levels [9,16]. Thus, we tested by CART analysis the
diagnostic performance of EZR-autoantibodies in con-
comitance with the above biomarkers: CA19.9 (using the
most relevant clinical laboratory cut-off value of 37 IU/ml)
and ENOA1,2-autoantibodies, in the cohort of samples
where all three parameters were available (PDAC patients:
n = 45; HS, AD, CP: n = 48) (Figure 4D). Using this
approach, the first node that significantly discrimina-
ted PDAC patients from benign controls was CA19.9 (P <
0.001). EZR-autoantibodies significantly refined CA19.9
diagnostic performance, particularly in CA19.9-negative
cases (P < 0.0001). Finally, in the few cases in which
CA19.9 and EZR-autoantibodies yielded conflicting re-
sults (i.e. CA19.9 negative/EZR-autoantibodies posi-
tive), ENOA1,2-autoantibodies significantly improved
diagnostic performance (P = 0.0022). Since only one
control subject in our cohort displayed high CA19.9
serum levels, CART analysis could not further classify
CA19.9 positive cases. However, among CA19.9 positive
cases only one PDAC patient and the above mentioned
control subject resulted negative for EZR-autoantibodies,
and they were again properly classified by ENOA1,2-auto-
antibodies. Based on these findings, a diagnostic algorithm
which assigned patients to the PDAC group when both
EZR-autoantibodies and CA19.9 were positive, and sepa-
rated discordant cases into PDAC or controls based on
Figure 4 Diagnostic performance of EZR-autoantibodies captured by ELISA. (A) Scatter plots show the reactivity of PDAC (n = 69), healthy
subject (HS, n = 45), non-PDAC (n = 28), autoimmune disease (AD, n = 12) and chronic pancreatitis (CP, n = 37) patient sera to EZR recombinant
protein as assessed by ELISA: PDAC vs. HS, non-PDAC and CP P < 0.0001; PDAC vs. AD P = 0.0006. (B) Scatter plots show the reactivity of
prediagnostic PDAC patient (n = 16) and matched control (n = 32) sera from the EPIC cohort to EZR recombinant protein as assessed by ELISA:
PDAC vs. controls P = 0.0002. Reactivity is expressed as optical density (O.D.) read at 450 nm, P-values were calculated by Student's t-test. (C) ROC
analysis of EZR-autoantibody sensitivity and specificity using O.D. obtained in ELISA as a continuous variable (cut-off value: O.D. = 0.1183).
(D) Classification and regression tree (CART) analysis of CA19.9 serum levels (≥ 37 IU/ml), EZR-autoantibody reactivity (O.D.≥ 0.1183) and
ENOA1,2-autoantibody reactivity (expressed as 2DE WB positivity) with 93 PDAC patients and controls where all parameters were available. The
number and percentage of PDAC patients and controls are shown for each node. (E) ROC analysis of sensitivity and specificity of EZR-
autoantibody detection in combination with CA19.9 and ENOA1,2-autoantibodies in the cohort of samples where all three parameters were
available (PDAC patients: n = 45; benign controls: HS, AD, CP, n = 48). The applied diagnostic algorithm assigns patients to the PDAC group when
both EZR-autoantibodies and CA19.9 are positive, and separates discordant cases into PDAC or controls based on the presence or absence
of ENOA1,2-autoantibodies.
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respectively, resulted in 100% sensitivity and 92.3% speci-
ficity, with an overall diagnostic accuracy (AUC) of 0.96 ±
0.02 (Figure 4E). The diagnostic performance of EZR-
autoantibody, CA19.9 and ENOA1,2-autoantibody tested
individually in the same cohort is shown in Additional file
1: Figure S4.While EZR autoantibodies have diagnostic potential,
they did not show the prognostic value we have pre-
viously reported for ENOA1,2 [9]. Even though PDAC
patients who had experienced disease control (either
partial response or stable disease) upon first-line che-
motherapy had significantly (P = 0.030) higher mean and
median OD values in the EZR ELISA, EZR-autoantibodies
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impact on survival (PFS or OS), either following surgery
with radical intent or first-line chemotherapy. This dem-
onstrates the power of the SERPA approach, combined
with ELISA, to identify antigens that could serve distinct
functions in an armament of tools for the diagnosis and
prognosis of PDAC.
Discussion
This study identifies autoantibodies to EZR as early
markers in mouse and human PDAC. Of clinical rele-
vance, we also show that EZR-autoantibodies efficiently
complement the diagnostic performance of CA19.9.
To identify early immune response markers we applied
SERological Proteome Analysis (SERPA) in KC and KPC
mice spontaneously developing PDAC. As GEM can be
sampled at defined stages of tumor development and
under controlled breeding conditions, greater standardi-
zation is possible when using mouse models as opposed
to human studies. GEM allowed us to identify EZR-
autoantibodies as early biomarkers in PDAC, since
precociously detected in their serum when the disease
stage was limited to PanIN. Through this approach, we
also identified additional antigens (VCL, PDC6I, FUBP2,
hnRNPL, VIM, K2C8, ANXA1 e ANXA2) recognized at
high frequencies by both KC and KPC sera.
Reactivity against some of these antigens was present
in control mice, but the intensity of WB recognition was
much greater in GEM. A clear example is represented
by EZR, faintly recognized by a number of control mice
but strongly evident in all KPC. Despite the fact that
auto-reactive lymphocytes should have been removed
from the repertoire before maturation into naïve B cells,
a large number of circulating IgG+ memory B cells pro-
duce low affinity antibodies to self-antigens [17,18]. The
humoral response against these self-antigens is strongly
increased in tumor conditions, as demonstrated in this
work both in humans and in mice (Figure 1, Table 3 and
Figure 4). Some differences in the pattern of recognition
were present between mice of the same age, probably
due to the molecular heterogeneity of tumor progression
in this model that fully recapitulates the genetic and
molecular features of human PDAC [12]. Importantly,
all the identified antigens, except for FUBP2 and
ANXA1, induced a powerful humoral response not only
in KPC but also in KC bearing PanIN lesions, indicating
that the antibody response to these TAAs is already
occurring when Kras is the only genetic alteration in the
tumor, independently of p53 mutation, which is a later
event in PDAC development. This reflects previous
studies reporting how the immune response to TAAs in
humans occurs at an early stage during tumorigenesis,
as illustrated by the detection of high titers of autoanti-
bodies, as early as 5 years before disease onset [19,20].By comparing the 2DE WB reactivity of GEM with
that of a large cohort of PDAC patients and controls, six
proteins, namely: EZR, ANXA2, VCL, hnRNPL, ANXA1
and PDC6I were common to both human and mouse
signatures. EZR and ANXA2 were recognized by most
PDAC patients who underwent surgery with curative in-
tent. ELISA confirmed the diagnostic value of anti-EZR
but not anti-ANXA2 autoantibodies, which were also
present in control groups. Other studies have indeed
reported the presence of autoantibodies against ANXA2
in systemic autoimmune diseases and lung cancer, as
well as pancreatic cancer [21-23], suggesting that the
humoral response to ANXA2 is not specific for PDAC
transformation.
EZR is a member of the ezrin-radixin-moesin (ERM)
family and a link between a number of growth factor
receptors/adhesion molecules and the actin cytoskeleton. It
is localized to the cytoplasm as an inactive form. Upon
threonine and tyrosine phosphorylation, EZR is transported
to the cell membrane whereupon it tethers F-actin [24]. It
works downstream of cell-surface receptors through
the activation of Rho and PI3K/Akt signaling pathways
[25,26], and in physiological conditions, EZR is required
for macropinocytosis, cell adhesion, and membrane
ruffling in epithelial cells, whereas in tumor cells it is an
important metastatic regulator [27]. EZR is overexpressed
in many cancers, including PDAC, even in PanIN lesions
[28-30], and it interacts with cortactin to form podosomal
rosettes in PDAC cells, which may play an important role
in tumor invasion [31]. These observations support the
immunogenicity of EZR that we observed in the present
study, even if it is not clear how TAAs overcome self-
tolerance and thus become autoantibody targets in cancer
patients, as many of those discovered so far are intracellu-
lar proteins [4,32,33]. Interestingly, EZR has been identi-
fied both in exosomes secreted by mesothelioma cells [34]
and as a substrate of matrix metalloproteinases able to
generate neo-epitopes from self-antigens [35].
The most important observation of our study is that
autoantibodies against EZR were present also in pre-
diagnostic PDAC samples from the prospective EPIC
cohort that were collected several months or years
before PDAC diagnosis. The EPIC study recruited over
half a million healthy volunteers in ten European coun-
tries, including Italy, monitored longitudinally for cancer
or other disease development [36]. Since it has been esti-
mated that the elapsed time between PDAC initiation to
metastatic spread is at least 10 years [37], our results
strongly support the hypothesis that EZR-autoantibody
development is an early event in PDAC. Notably, pre-
diagnostic patients with the highest levels of EZR-
autoantibody in the ELISA test were the ones with an
intermediate time lag to diagnosis (69.3 and 56.9 mo,
Additional file 1: Table S3). This observation supports the
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diagnosis due to immune complex formation [20].
Although EZR-autoantibody testing has displayed a
high diagnostic performance, especially in resectable
PDAC patients (Additional file 1: Figure S4), a single
TAA may lack adequate sensitivity and specificity, and
the combination of a panel of autoantibodies and sero-
logical markers can improve the overall accuracy of a
diagnostic assay for cancer detection. We therefore
assessed the diagnostic performance of combined dicho-
tomized EZR-autoantibody levels, CA19.9, the only
PDAC marker currently in clinical use, and ENOA1,2-
autoantibodies. We have previously demonstrated that
autoantibodies against Ser-419-phosphorylated ENOA
isoforms (ENOA1,2) complement the performance of
CA.19.9 [9]. Interestingly, a diagnostic algorithm separ-
ating CA19.9 and EZR-autoantibodies discordant cases
into PDAC or controls based on the presence or absence
of ENOA1,2-autoantibodies respectively, resulted in an
overall diagnostic accuracy of 0.96. Notably, the algorithm
here applied is more stringent than the one previously de-
scribed by our group [9], where tested cases were assigned
to the PDAC group when either ENOA1,2-autoantibodies
or CA19.9 were positive, as their values were inversely
correlated. This finding is of real translational relevance,
since CA19.9 is the only biomarker with demonstrated
clinical value for therapeutic monitoring and detection of
recurrent PDAC, but its use as a screening tool has proved
unsuccessful until now [3].
Further validation studies, performed in a large and in-
dependent patient cohort, are warranted to establish the
diagnostic performance of this multiplexed analysis and of
the identified TAA panel tested alone or in combination.
Additional file
Additional file 1: Figure S1. Survival curve and histological progression
of KC and KPC. Table S1. Identification of proteins recognized by GEM
sera using MALDI-TOF MS. Table S2. Identification of proteins recognized
by PDAC patient sera using MALDI-TOF MS. Figure S2. Immunoreactivity
of PDAC patient and control sera against CF-PAC-1 cell line 2DE map.
Figure S3. Validation of EZR identification by Western blot analysis.
Table S3. Time span to diagnosis and EZR-autoantibody ELISA values of
PDAC patients from the EPIC cohort. Figure S4. ROC analysis of
individually evaluated EZR-autoantibody, dichotomized CA19.9 serum
level and ENOA1,2-autoantibody.
Abbreviations
2DE: Two dimensional electrophoresis; AD: Autoimmune disease;
ANXA1: Annexin A1; ANXA2: Annexin A2; AU: Arbitrary units; AUC: Area
under the curve; CART: Classification and regression tree; CP: Chronic
pancreatitis; ECOG PS: Eastern cooperative oncology group performance
status; ELISA: Enzyme-linked immunosorbent assay; ENOA: α-enolase;
EPIC: European Prospective Investigation into Cancer and Nutrition;
ERM: Ezrin-radixin-moesin; EZR: Ezrin; FUBP2: Far upstream element binding
protein 2; GEM: Genetically engineered mice; hnRNPL: Heterogeneous
nuclear ribonucleoprotein L; HRP: Horseradish peroxidase; HS: Healthy
subject; K2C8: Cytokeratin-8; KC: LSL-KrasG12D/+, Pdx-1-Cre mice; KPC: LSL-
KrasG12D/+, LSL-Trp53R172H/+, Pdx-1-Cre mice; MALDI-TOF: Matrix-assisted laserdesorption ionization-time of flight; MS: Mass spectrometry; non-PDAC:
Non-pancreatic cancer; NP: Normal pancreas; OD: Optical density;
PanIN: Pancreatic intraepithelial neoplasia; PDAC: Pancreatic ductal
adenocarcinoma; PDC6I: Programmed cell death-6 interacting protein;
Pdx-1: Pancreatic duodenum homeobox 1; ROC: Receiver operating curve;
SEREX: Serological analysis of tumor antigens by recombinant cDNA
expression cloning; SERPA: Serological proteome analysis; TAA: Tumor-
associated antigen; VCL: Vinculin; VIM: Vimentin; WB: Western blot.
Competing interests
FN, MC, and PC are inventors of an Italian patent application No:
TO2012A000523 entitled “Kit for in vitro diagnosis and predisposition
assessment of pancreatic ductal adenocarcinoma”. Potential investigator
conflict of interest has been disclosed to study participants.
Authors’ contributions
MC designed the study, performed human SERPA and ELISA experiments,
analyzed the data and wrote the manuscript; PC designed the study,
coordinated and performed GEM breeding, murine sample collection and
analyzed data; FCL performed murine SERPA studies and GEM serum
collection; MG contributed to GEM breeding and analyzed data;
RC performed GEM histological and immunohistochemical analysis; IS
performed statistical analysis; GM performed mass spectrometry analysis;
SB and SB performed human histological and immunohistochemical analysis;
SB performed microarray analysis; AN, PN, PS, AS, CB and MM recruited
patients and contributed to experimental design and analysis of data;
AN, CS and PV provided samples from the Turin EPIC cohort and analyzed
data; FN supervised the project and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported in part by grants from: the European Community,
Seventh Framework Program European Pancreatic Cancer-Tumor
-Microenvironment Network (EPC-TM-Net, no. 256974); Associazione Italiana
Ricerca sul Cancro (AIRC) 5 × 1000 (no. 12182) and IG (no. 5548 and 11643);
Ministero della Salute: Progetto Integrato Oncologia; Regione Piemonte:
Ricerca Industriale e Sviluppo Precompetitivo (BIOPRO and ONCOPROT),
Ricerca Industriale “Converging Technologies” (BIOTHER), Progetti strategici
su tematiche di interesse regionale o sovra regionale (IMMONC), Ricerca
Sanitaria Finalizzata, Ricerca Sanitaria Applicata; Ministero dell’Istruzione e
della Ricerca (MIUR), Progetti di Rilevante Interesse Nazionale (PRIN 2009);
University of Turin-Progetti di Ateneo 2011: Mechanisms of REsistance to
anti-angiogenesis regimens THErapy (grant Rethe-ORTO11RKTW). MC is
recipient of a fellowship from the Fondazione Italiana Ricerca sul
Cancro (FIRC).
We thank Drs. Marianne Murphy, John Iliffe and Radhika Srinivasan for
critically reading the manuscript.
Author details
1Center for Experimental Research and Medical Studies (CeRMS), Azienda
Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy.
2Department of Molecular Biotechnology and Life Sciences, University of
Torino, Turin, Italy. 3Division of Biostatistics, Regina Elena National Cancer
Institute, Rome, Italy. 4Centro Oncologico Ematologico Subalpino (COES),
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy.
5Gastroenterology Unit, Ordine Mauriziano Hospital, Turin, Italy. 6Human
Genetics Foundation, HuGeF, Turin, Italy. 7Unit of Cancer Epidemiology,
University of Turin and Center for Cancer Epidemiology and Prevention (CPO
Piemonte), Turin, Italy. 8ARC-NET Research Center, University of Verona,
Verona, Italy. 9Department of Pathology and Diagnostics, University of
Verona, Verona, Italy. 10Department of Surgery and Oncology, University of
Verona, Verona, Italy. 11Division of Immunology, Regina Elena National
Cancer Institute, Rome, Italy. 12Epigenetics Unit, Department of Surgery and
Cancer, Imperial College, London, UK. 13Division of Medical Oncology, Regina
Elena National Cancer Institute, Rome, Italy.
Received: 17 July 2013 Accepted: 20 August 2013
Published: 6 September 2013
References
1. Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362:1605–1617.
Capello et al. Journal of Hematology & Oncology 2013, 6:67 Page 12 of 12
http://www.jhoonline.org/content/6/1/672. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
3. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini
A, Topolcan O, Heinemann V: Tumor markers in pancreatic cancer: a
European Group on Tumor Markers (EGTM) status report. Ann Oncol
2010, 21:441–447.
4. Tan HT, Low J, Lim SG, Chung MC: Serum autoantibodies as biomarkers
for early cancer detection. FEBS J 2009, 276:6880–6904.
5. Hanash S: Harnessing immunity for cancer marker discovery.
Nat Biotechnol 2003, 21:37–38.
6. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A,
Ciuffreda L, Bertetto O, De Angelis C, Gaia E, et al: Autoantibody signature
in human ductal pancreatic adenocarcinoma. J Proteome Res 2007,
6:4025–4031.
7. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C,
Migliorini P, Perconti G, Giallongo A, Milella M, et al: An integrated humoral
and cellular response is elicited in pancreatic cancer by alpha-enolase, a
novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer
2009, 125:639–648.
8. Capello M, Ferri-Borgogno S, Cappello P, Novelli F: alpha-Enolase: a
promising therapeutic and diagnostic tumor target. FEBS J 2011,
278:1064–1074.
9. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P,
Salacone P, Novarino A, Giacobino A, Ciuffreda L, et al: Circulating
autoantibodies to phosphorylated alpha-enolase are a hallmark of
pancreatic cancer. J Proteome Res 2011, 10:105–112.
10. Leach SD: Mouse models of pancreatic cancer: the fur is finally flying!
Cancer Cell 2004, 5:7–11.
11. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross
S, Conrads TP, Veenstra TD, Hitt BA, et al: Preinvasive and invasive ductal
pancreatic cancer and its early detection in the mouse. Cancer Cell 2003,
4:437–450.
12. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH,
Rustgi AK, Chang S, Tuveson DA: Trp53R172H and KrasG12D cooperate to
promote chromosomal instability and widely metastatic pancreatic
ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469–483.
13. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR,
Hemon B, Casagrande C, Vignat J, et al: European Prospective
Investigation into Cancer and Nutrition (EPIC): study populations and
data collection. Public Health Nutr 2002, 5:1113–1124.
14. Chuang SC, Stolzenberg-Solomon R, Ueland PM, Vollset SE, Midttun O,
Olsen A, Tjonneland A, Overvad K, Boutron-Ruault MC, Morois S, et al:
A U-shaped relationship between plasma folate and pancreatic cancer
risk in the European Prospective Investigation into Cancer and Nutrition.
Eur J Cancer 2011, 47:1808–1816.
15. Barbero G, Carta F, Giribaldi G, Mandili G, Crobu S, Ceruti C, Fontana D,
Destefanis P, Turrini F: Protein/RNA coextraction and small two-
dimensional polyacrylamide gel electrophoresis for proteomic/gene
expression analysis of renal cancer biopsies. Anal Biochem 2006,
349:62–71.
16. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF:
Mass spectrometry analysis of the post-translational modifications of
alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome
Res 2010, 9:2929–2936.
17. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC:
Predominant autoantibody production by early human B cell precursors.
Science 2003, 301:1374–1377.
18. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H:
Autoreactivity in human IgG +memory B cells. Immunity 2007,
26:205–213.
19. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer
HER-2/neu protein-specific antibody can be detected in patients with
early-stage breast cancer. J Clin Oncol 1997, 15:3363–3367.
20. Ladd JJ, Chao T, Johnson MM, Qiu J, Chin A, Israel R, Pitteri SJ, Mao J, Wu M,
Amon LM, et al: Autoantibody signatures involving glycolysis and
splicesome proteins precede a diagnosis of breast cancer among
postmenopausal women. Cancer Res 2013, 73:1502–1513.
21. Salle V, Maziere JC, Smail A, Cevallos R, Maziere C, Fuentes V, Tramier B,
Makdassi R, Choukroun G, Vittecoq O, et al: Anti-annexin II antibodies in
systemic autoimmune diseases and antiphospholipid syndrome. J Clin
Immunol 2008, 28:291–297.22. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash
SM: An immune response manifested by the common occurrence of
annexins I and II autoantibodies and high circulating levels of IL-6 in
lung cancer. Proc Natl Acad Sci USA 2001, 98:9824–9829.
23. Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M,
Sharma R, Le DT, et al: Tyrosine 23 phosphorylation-dependent cell-
surface localization of annexin A2 is required for invasion and
metastases of pancreatic cancer. PLoS One 2011, 6:e19390.
24. Fehon RG, McClatchey AI, Bretscher A: Organizing the cell cortex: the role
of ERM proteins. Nat Rev Mol Cell Biol 2010, 11:276–287.
25. Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med
2004, 10:201–204.
26. Chen Q, Zhang XH, Massague J: Macrophage binding to receptor VCAM-1
transmits survival signals in breast cancer cells that invade the lungs.
Cancer Cell 2011, 20:538–549.
27. Niggli V, Rossy J: Ezrin/radixin/moesin: versatile controllers of signaling
molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 2008,
40:344–349.
28. Torer N, Kayaselcuk F, Nursal TZ, Yildirim S, Tarim A, Noyan T, Karakayali H:
Adhesion molecules as prognostic markers in pancreatic
adenocarcinoma. J Surg Oncol 2007, 96:419–423.
29. Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, Giese T, Friess H,
Kleeff J: Moesin-dependent cytoskeleton remodelling is associated with
an anaplastic phenotype of pancreatic cancer. J Cell Mol Med 2010,
14:1166–1179.
30. Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J: Ezrin promotes invasion and
metastasis of pancreatic cancer cells. J Transl Med 2010, 8:61.
31. Kocher HM, Sandle J, Mirza TA, Li NF, Hart IR: Ezrin interacts with cortactin
to form podosomal rosettes in pancreatic cancer cells. Gut 2009,
58:271–284.
32. Zinkernagel RM: What is missing in immunology to understand
immunity? Nat Immunol 2000, 1:181–185.
33. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang
C, Zeng Q: Targeting intracellular oncoproteins with antibody therapy or
vaccination. Sci Transl Med 2011, 3:99ra85.
34. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB,
Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN: Proteomic analysis
of exosomes secreted by human mesothelioma cells. Am J Pathol 2004,
164:1807–1815.
35. Cauwe B, Martens E, Proost P, Opdenakker G: Multidimensional
degradomics identifies systemic autoantigens and intracellular matrix
proteins as novel gelatinase B/MMP-9 substrates. Integr Biol (Camb) 2009,
1:404–426.
36. Bingham S, Riboli E: Diet and cancer–the European Prospective
Investigation into Cancer and Nutrition. Nat Rev Cancer 2004, 4:206–215.
37. Costello E, Neoptolemos JP: Pancreatic cancer in 2010: new insights for
early intervention and detection. Nat Rev Gastroenterol Hepatol 2011,
8:71–73.
doi:10.1186/1756-8722-6-67
Cite this article as: Capello et al.: Autoantibodies to Ezrin are an early
sign of pancreatic cancer in humans and in genetically engineered
mouse models. Journal of Hematology & Oncology 2013 6:67.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
